Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P-L Lollini

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
British Journal of Cancer|December 23, 1998
Wild-type p53-mediated down-modulation of interleukin 15 and interleukin 15 receptors in human rhabdomyosarcoma cellsC De Giovanni, P Nanni, A Sacchi, et al.
Clinical and Experimental Medicine|February 20, 2009
Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the gastrointestinal stromal tumors modelM A Pantaleo, L Landuzzi, G Nicoletti, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 8, 2000
Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytesM Giovarelli, P Cappello, G Forni, et al.
Oncogene|February 1, 2011
Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signalingC Garofalo, M C Manara, G Nicoletti, et al.
The Journal of Experimental Medicine|November 7, 2001
Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic miceP Nanni, G Nicoletti, C De Giovanni, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 25, 2000
DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c miceS Rovero, A Amici, E Di Carlo, et al.
Oncogene|September 20, 2016
Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancerL Castagnoli, G C Ghedini, A Koschorke, et al.
International Journal of Cancer|June 22, 2000
p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinomaP Nanni, S M Pupa, G Nicoletti, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 21, 1999
A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactionsM Giovarelli, P Musiani, G Garotta, et al.
The Journal of Experimental Medicine|August 4, 1998
Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic miceK Boggio, G Nicoletti, E Di Carlo, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
British Journal of Cancer|December 23, 1998
Wild-type p53-mediated down-modulation of interleukin 15 and interleukin 15 receptors in human rhabdomyosarcoma cellsC De Giovanni, P Nanni, A Sacchi, et al.
Clinical and Experimental Medicine|February 20, 2009
Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the gastrointestinal stromal tumors modelM A Pantaleo, L Landuzzi, G Nicoletti, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 8, 2000
Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytesM Giovarelli, P Cappello, G Forni, et al.
Oncogene|February 1, 2011
Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signalingC Garofalo, M C Manara, G Nicoletti, et al.
The Journal of Experimental Medicine|November 7, 2001
Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic miceP Nanni, G Nicoletti, C De Giovanni, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 25, 2000
DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c miceS Rovero, A Amici, E Di Carlo, et al.
Oncogene|September 20, 2016
Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancerL Castagnoli, G C Ghedini, A Koschorke, et al.
International Journal of Cancer|June 22, 2000
p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinomaP Nanni, S M Pupa, G Nicoletti, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 21, 1999
A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactionsM Giovarelli, P Musiani, G Garotta, et al.
The Journal of Experimental Medicine|August 4, 1998
Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic miceK Boggio, G Nicoletti, E Di Carlo, et al.
Pageof 11